Semaglutide 2.4 mg: Cost-Effective MASH Treatment

Jul 26, 2026 · Published in: PharmacoEconomics

Background Information

Semaglutide 2.4 mg offers cost-effective treatment for MASH.

Non-cirrhotic metabolic dysfunction-associated steatohepatitis (MASH) with fibrosis has significant clinical and economic impacts, necessitating effective treatments. Semaglutide 2.4 mg increased quality-adjusted life years (QALYs) by 1.66 with an incremental cost of US$33,031, presenting the most favorable cost-effectiveness profile. Semaglutide 2.4 mg is likely cost-effective at standard willingness-to-pay thresholds, suggesting it could be a preferred treatment in clinical practice for MASH. Semaglutide 2.4 mg offers cost-effective treatment for MASH with favorable outcomes.

📊 Deep Analysis Available

Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report.

Subscribe for Full Access →

Authors: McGovern AJ, Cinfio F, Luo R

Citation: McGovern AJ, Cinfio F, Luo R A Cost-Effectiveness Model of Semaglutide 2.4 mg, Resmetirom 80 mg, and Resmetirom 100 mg Versus Standard of Care for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis in the United States. PharmacoEconomics. 2026. doi:10.1007/s40273-026-01647-8

Article Links: PubMed · Journal / DOI

🎓

Reviewed by a licensed pharmacist

Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.

Accurate and up-to-date information is our highest priority.

If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.

Suggest a correction Request a topic

Thanks for the feedback!

Deep Analysis Pending

The deep analysis for this article is pending full-text access. We only publish a full clinical breakdown once we have the complete paper, not just the abstract. The PubMed abstract is linked above in the meantime.